Automated capillary Western dot blot method for the identity of a 15-valent pneumococcal conjugate vaccine

被引:23
|
作者
Hamm, Melissa [1 ]
Ha, Sha [1 ]
Rustandi, Richard R. [1 ]
机构
[1] Merck Res Labs, Vaccine Analyt Dev, West Point, PA 19486 USA
关键词
Pneumococcal conjugate vaccine; Dot blot; Capillary Western; Simple Western; CRM197; Polysaccharide; POLYSACCHARIDES; QUANTITATION; SYSTEM;
D O I
10.1016/j.ab.2015.03.021
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Simple Western is a new technology that allows for the separation, blotting, and detection of proteins similar to a traditional Western except in a capillary format. Traditionally, identity assays for biological products are performed using either an enzyme-linked immunosorbent assay (ELISA) or a manual dot blot Western. Both techniques are usually very tedious, labor-intensive, and complicated for multivalent vaccines, and they can be difficult to transfer to other laboratories. An advantage this capillary Western technique has over the traditional manual dot blot Western method is the speed and the automation of electrophoresis separation, blotting, and detection steps performed in 96 capillaries. This article describes details of the development of an automated identity assay for a 15-valent pneumococcal conjugate vaccine, PCV15-CRM197, using capillary Western technology. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:33 / 39
页数:7
相关论文
共 50 条
  • [31] Development and qualification of an automated capillary Western method for the identification of polysaccharide serotypes in pneumococcal conjugate vaccine (PCV)
    Deiss, Alyssa
    Loughney, John W.
    Rustandi, Richard R.
    Vuolo, Kimberly
    Mackey, Megan A.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2024, 238
  • [32] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
    Stacey, Helen L.
    Rosen, Jeffrey
    Peterson, James T.
    Williams-Diaz, Angela
    Gakhar, Vanita
    Sterling, Tina M.
    Acosta, Camilo J.
    Nolan, Katrina M.
    Li, Jianing
    Pedley, Alison
    Benner, Patrice
    Abeygunawardana, Chitrananda
    Kosinski, Michael
    Smith, William J.
    Pujar, Hari
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 530 - 539
  • [33] Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries
    Hu, Tianyan
    Weiss, Thomas
    Bencina, Goran
    Owusu-Edusei, Kwame
    Petigara, Tanaz
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1098 - 1107
  • [34] HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) SEROTYPES IN CHILDREN IN HONG KONG
    Mohanty, S.
    Sukarom, I
    Cheng, S. S. Y.
    Owusu-Edusei, K.
    Hu, T.
    VALUE IN HEALTH, 2020, 23 : S555 - S555
  • [35] HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) SEROTYPES IN CHILDREN IN SOUTH KOREA
    Mohanty, S.
    Sukarom, I
    Yang, G.
    Park, J.
    Owusu-Edusei, K.
    Hu, T.
    VALUE IN HEALTH, 2020, 23 : S550 - S550
  • [36] HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN ADULTS 65 YEARS AND OLDER IN 5 EUROPEAN COUNTRIES
    Deb, A.
    Johnson, K.
    Bencina, G.
    Malik, T.
    VALUE IN HEALTH, 2019, 22 : S657 - S657
  • [37] Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults infected with HIV: a phase III trial
    Mohapi, L.
    Osiyemi, O.
    Supparatpinyo, K.
    Ratanasuwan, W.
    Molina, J.
    Dagan, R.
    Tamms, G.
    Sterling, T.
    Zhang, Y.
    Hartzel, J.
    Pedley, A.
    Kan, Y.
    Hurtado, K.
    Buchwald, U.
    Musey, L.
    Simon, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 16 - 16
  • [38] The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
    Shi, Yaru
    Nolan, Katrina M.
    Burton, Robert L.
    Shekar, Tulin
    Murphy, Rocio D.
    Banniettis, Natalie
    Musey, Luwy
    Buchwald, Ulrike K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [39] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033)
    Suzuki, Hiroko
    Fujita, Hidetoshi
    Iwai, Kazuyuki
    Kuroki, Haruo
    Taniyama, Kazuhiko
    Shizuya, Toshiyuki
    Kishino, Hiroyuki
    Igarashi, Rie
    Shirakawa, Masayoshi
    Sawata, Miyuki
    VACCINE, 2023, 41 (34) : 4933 - 4940
  • [40] SAFETY, TOLERABILITY AND IMMUNOGENICITY OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE+PPV23 12 MONTHS LATER IN HEALTHY ADULTS ≥ 50
    Song, J. -Y.
    Chang, C. -J.
    Andrews, C.
    Diez-Domingo, J.
    Oh, M. -D.
    Dagan, R.
    Musey, L.
    Buchwald, U. K.
    Hartzel, J.
    Pedley, A.
    Li, J.
    Sterling, T.
    Tamms, G.
    Chiarappa, J. A.
    Lutkiewicz, J.
    Tu, Y.
    AGE AND AGEING, 2022, 51 (SUPPL 2)